EYPT - EyePoint Pharmaceuticals, Inc.
13.62
-0.360 -2.643%
Share volume: 764,199
Last Updated: 05-12-2026
Measuring And Control Equipment/Lab Analytical Instruments:
-0.07%
PREVIOUS CLOSE
CHG
CHG%
$13.98
-0.36
-0.03%
View ratios
| Fiscal Date | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | 03-31-2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
| Report Date | 08-08-2024 | 11-07-2024 | 03-06-2025 | 05-08-2025 | 08-07-2025 | 11-06-2025 | 03-05-2026 | 05-07-2026 | |
| Assets | |||||||||
| Total Assets | 324.249 M | 300.917 M | 418.465 M | 362.564 M | 301.147 M | 251.695 M | 363.996 M | 288.217 M | |
| Current Assets | 294.931 M | 268.549 M | 383.306 M | 326.983 M | 265.251 M | 216.106 M | 328.655 M | 249.504 M | |
| Inventories | 3.672 M | 2.807 M | 2.305 M | 2.129 M | 2.678 M | 2.110 M | 1.813 M | 1.250 M | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 189.479 M | 173.963 M | 271.209 M | 233.036 M | 184.590 M | 129.445 M | 204.265 M | 144.833 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 90.769 M | 79.830 M | 99.704 M | 85.158 M | 71.143 M | 74.577 M | 101.821 M | 77.712 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 6.899 M | 8.391 M | 8.177 M | 8.044 M | 8.762 M | 8.861 M | 9.023 M | 9.482 M | |
| Other Assets | 22.419 M | 23.977 M | 26.982 M | 27.537 M | 27.134 M | 26.728 M | 26.318 M | 29.231 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 324.249 M | 300.917 M | 418.465 M | 362.564 M | 301.147 M | 251.695 M | 363.996 M | 288.217 M | |
| Total liabilities | 95.944 M | 82.183 M | 81.964 M | 64.168 M | 55.138 M | 51.513 M | 57.883 M | 57.745 M | |
| Total current liabilities | 62.102 M | 48.794 M | 49.048 M | 41.677 M | 33.175 M | 30.094 M | 37.024 M | 37.460 M | |
| Accounts Payable | 14.296 M | 7.343 M | 11.721 M | 16.419 M | 19.685 M | 10.076 M | 10.490 M | 18.813 M | |
| Other liabilities | 22.164 M | 22.155 M | 22.063 M | 22.491 M | 21.963 M | 21.419 M | 20.859 M | 20.285 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 22.164 M | 22.155 M | 22.063 M | 22.491 M | 21.963 M | 21.419 M | 20.859 M | 20.285 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 228.305 M | 218.734 M | 336.501 M | 298.396 M | 246.009 M | 200.182 M | 306.113 M | 230.472 M | |
| Common stock | 1.030 B | 1.049 B | 1.208 B | 1.216 B | 1.223 B | 1.237 B | 1.410 B | 1.419 B | |
| Retained earnings | -802.256 M | -831.617 M | -873.016 M | -918.211 M | -977.637 M | -1.037 B | -1.105 B | -1.190 B |